All studies
Phase 3RecruitingInterventionalNCT07577843

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease (DUET ENCORE-CD)

A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • Crohn Disease
I want to take partRefer a patient8 sites in India · 287 worldwide

At a glance

Phase
Phase 3
Study type
Interventional
Sponsor
Janssen Research & Development, LLC
Enrolment target
460
Started
22 May 2026
Main results due (estimated)
12 June 2028
Study ends (estimated)
12 July 2030
Allocation
Randomized
Design
Parallel
Purpose
Treatment
Masking
Double (participant, investigator)
Sites
287 · 8 in India
First posted
11 May 2026
Registry updated
3 November 2026

Can you take part?

  • Aged 18 years and over.
  • Open to any sex.
  • You need the condition being studied. Healthy volunteers are not accepted.

Age groups: adult, older adult.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion criteria:

* Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (\>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
* Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score \>= 220 but less than or equal to (\<=) 450 and either: a. Mean daily stool frequency (SF) count \>= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score \>= 2.0, based on the unweighted CDAI component of abdominal pain (AP)
* Have moderately to severely active ileal and/or colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria
* Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies

Exclusion criteria:

* Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, ulcerative colitis (UC) or clinical findings highly suggestive of UC
* Complications of CD such as symptomatic bowel strictures or stenoses, or any other manifestation that may require intestinal surgery while enrolled in the study
* Presence of draining (that is, functioning) stoma or ostomy
* Has a history of short bowel syndrome, is missing greater than (\>) 2 of the 5 ileocolonic segments, or has any other medical condition that could preclude or confound the ability to use efficacy assessment tools (such as CDAI) to assess response to study intervention
* Currently has or is suspected of having an abscess

What this study is about

In the sponsor’s own words, from the registry.

The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive \[worsens with time\] and life-threatening disease of the intestine).

What participants receive

  • Experimental

    JNJ-78934804

    Participants will receive JNJ-78934804 induction dose, at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.

    Drug: JNJ-78934804

  • Active comparator

    Guselkumab

    Participants will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12. All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28. Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the LTE phase.

    Drug: JNJ-78934804 · Drug: Guselkumab

Interventions

  • JNJ-78934804Drug

    Also known as JNJ-4804

    JNJ-78934804 will be administered subcutaneously.

  • GuselkumabDrug

    Also known as TREMFYA

    Guselkumab will be administered subcutaneously.

What the study measures

Primary outcomes

  1. Co-Primary: Percentage of Participants with Clinical Remission at Week 48

    Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than (\<) 150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 48

  2. Co-Primary: Percentage of Participants with Endoscopic Remission at Week 48

    Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of less than or equal to (\<=) 4 with at least a 2-point reduction from baseline and no subscore greater than (\>) 1 in any individual component. The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 48

Secondary outcomes

  1. Percentage of Participants with Deep Remission at Week 48

    Deep remission (composite endpoint) is defined as achieving both clinical remission and endoscopic remission at Week 48 at the participant level. Clinical remission is defined as a CDAI score of \<150 and Endoscopic remission is defined as a SES-CD score of \<= 4 with at least a 2-point reduction from baseline and no subscore \>1 in any individual component. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 48

  2. Percentage of Participants with Corticosteroid-Free (90-Day) Clinical Remission at Week 48

    Corticosteroid-free (90-day) clinical remission at Week 48 is defined as clinical remission at Week 48 and not receiving corticosteroids for at least 90 days prior to Week 48. Clinical remission is defined as a CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 48

  3. Percentage of Participants with Corticosteroid-Free (90-day) PRO-2 Remission at Week 48

    Corticosteroid-free (90-day) patient-reported outcome(s) (PRO-2) remission at Week 48 is defined as an abdominal plan (AP) mean daily score less than or equal to (\<=) 1 and stool frequency (SF) mean daily score \<= 2.8, and no worsening of AP or SF from baseline, and not receiving corticosteroids for at least 90 days prior to Week 48.

    Time frame: At Week 48

  4. Percentage of Participants with Sustained Clinical Remission

    Sustained clinical remission is defined as clinical remission at Week 12 and Week 48. Clinical remission is defined as CDAI score of \<150. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Weeks 12 and 48

  5. Percentage of Participants with Histologic-Endoscopic Remission at Week 48

    Composite endpoint defined as achieving both histologic remission (defined as a Robarts Histopathology Index score less than or equal to \[\<=\] 3, where each of the items of lamina propria neutrophils, neutrophils in epithelium, and erosions or ulcerations must be equal to 0) and endoscopic remission at the participant level.

    Time frame: At Week 48

  6. Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48

    IBDQ response at Week 48 is defined as an improvement of at least 16 points in the IBDQ total score from baseline at Week 48. IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate disease-specific health related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, AP), systemic function (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week 48

  7. Percentage of Participants with Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Mental Component Summary Score (MCS) Response at Week 48

    PROMIS-29 MCS response at Week 48 is defined as an improvement of at least 7 points in PROMIS-29 MCS score from baseline at Week 48. The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities). PROMIS-29 also includes an overall average pain intensity 0-10 numeric rating scale. The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.

    Time frame: At Week 48

  8. Percentage of Participants with Clinical Remission at Week 12

    Clinical remission at Week 12 is defined as CDAI score \<150 at Week 12. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 12

  9. Percentage of Participants with Endoscopic Response at Week 12

    Endoscopic response at Week 12 is defined as greater than (\>) 50 percent (%) improvement from baseline in SES-CD score at Week 12 or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. SES-CD score can range from 0 to 56. Higher scores indicating more severe disease.

    Time frame: At Week 12

  10. Percentage of Participants with Clinical Response at Week 4

    Clinical response at week 4 is defined as \>=100-point reduction from baseline in CDAI score at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 4

  11. Percentage of Participants with Clinical Remission at Week 4

    Clinical remission at Week 4 is defined as CDAI score \<150 at Week 4. CDAI scores range from 0 to approximately 600. Higher score indicates higher disease activity.

    Time frame: At Week 4

  12. Number of Participants with Adverse Events (AE) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to approximately 3 years

Who is running it

Lead sponsor
Janssen Research & Development, LLC
Sponsor type
Industry
Responsible party
The sponsor
Organisation
Janssen Research & Development, LLC
Data monitoring committee
Yes
US FDA-regulated drug
Yes
US FDA-regulated device
No
Sponsor's study ID
78934804CRD3001
Other IDs
2026-525922-39-00
  • Janssen Research & Development, LLC Clinical Trial

    Study director

    Janssen Research & Development, LLC

Study sites(287)

  • Sushruta Multispecialty Hospital and Research Centre

    Hubli, India

    Recruiting

  • Asian Institute Of Gastroenterology

    Hyderabad, India

    Recruiting

  • S. R. Kalla Memorial General Hospital

    Jaipur, India

    Recruiting

  • Lisie Hospital

    Kochi, India

    Recruiting

  • P D Hinduja National Hospital and Medical Research Center

    Mumbai (ex Bombay), India

    Recruiting

  • Yashoda Super Speciality Hospitals

    Secunderabad, India

    Recruiting

  • SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre

    Surat, India

    Recruiting

  • Gujarat Gastro and Vascular Hospital

    Surat, India

    Recruiting

  • Mayo Clinic

    Scottsdale, Arizona, United States

    Recruiting

  • GIA Sun City

    Sun City, Arizona, United States

    Recruiting

  • Clinnova Research

    Anaheim, California, United States

    Recruiting

  • Gastro SB Clinic

    Chula Vista, California, United States

    Recruiting

  • United Medical Doctors

    Los Alamitos, California, United States

    Recruiting

  • Medical Associates Research Group, Inc.

    San Diego, California, United States

    Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado, United States

    Recruiting

  • Florida Research Center Inc.

    Lakewood Rch, Florida, United States

    Recruiting

  • Sanchez Clinical Research, Inc

    Miami, Florida, United States

    Recruiting

  • Endoscopic Research Inc

    Orlando, Florida, United States

    Recruiting

  • GCP Clinical Research

    Tampa, Florida, United States

    Recruiting

  • Atlanta Gastroenterology Specialists

    Suwanee, Georgia, United States

    Recruiting

  • Tri-State Gastroenterology Assoc

    Crestview Hills, Kentucky, United States

    Recruiting

  • Gastroenterology Clinic of Acadiana

    Lafayette, Louisiana, United States

    Recruiting

  • GIA Metairie

    Metairie, Louisiana, United States

    Recruiting

  • GIA Kansas City

    Lee's Summit, Missouri, United States

    Recruiting

  • New York Gastroenterology Associates

    New York, New York, United States

    Recruiting

  • GIA Rochester

    Rochester, New York, United States

    Recruiting

  • University of North Carolina Hospital

    Chapel Hill, North Carolina, United States

    Recruiting

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio, United States

    Recruiting

  • Digestive Disease Specialists Inc

    Oklahoma City, Oklahoma, United States

    Recruiting

  • The Oregon Clinic

    Portland, Oregon, United States

    Recruiting

  • Michigan Center of Medical Research

    Farmington Hill, Pennsylvania, United States

    Recruiting

  • Palmetto Primary and Specialty Care Physicians, Charleston

    Summerville, South Carolina, United States

    Recruiting

  • Gastro One

    Cordova, Tennessee, United States

    Recruiting

  • Tyler Research Institute, LLC

    Tyler, Texas, United States

    Recruiting

  • GIA Webster

    Webster, Texas, United States

    Recruiting

  • GIA Richmond

    Richmond, Virginia, United States

    Recruiting

  • GI Alliance Tacoma

    Tacoma, Washington, United States

    Recruiting

  • Sanatorio Duarte Quiroz

    Córdoba, Argentina

    Recruiting

  • GEDYT

    Famailla, Argentina

    Recruiting

  • Globalpsy

    La Plata, Argentina

    Recruiting

Showing 40 of 287 sites. 285 recruiting, 2 not recruiting and 0 cancelled; 8 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
Yes

The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Source: ClinicalTrials.gov record NCT07577843, status verified November 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.